Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma.
advanced glycation end products
multiple myeloma
oxidation
soluble receptor of advanced glycation end products
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
04 Mar 2019
04 Mar 2019
Historique:
received:
23
01
2019
revised:
26
02
2019
accepted:
03
03
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
7
3
2019
Statut:
epublish
Résumé
Glycative stress influences tumor progression. The aim of the present study was to evaluate the advanced glycation end products/soluble receptor of advanced glycation end products (AGE/sRAGE) axis in patients with multiple myeloma (MM). Blood samples were taken from 19 patients affected by MM and from 16 sex-matched and age-matched healthy subjects. AGE and sRAGE axis were dosed in patients with MM and matched with controls. AGEs were measured by spectrofluorimetric methods. Blood samples for the determination of sRAGE were analyzed by ELISA. AGE levels were significantly reduced in patients with respect to controls. Instead, sRAGE was significantly elevated in patients affected by MM compared to healthy subjects. Moreover, we showed that there was a statistically significant difference in sRAGE according to the heavy and light chain. IgA lambda had significantly higher sRAGE values than IgA kappa, IgG kappa, and IgG Lambda MM patients. From our data emerges the role of the sRAGE/AGE axis in MM. Since AGE is a positive regulator of the activity of RAGE, circulating sRAGE concentrations may reflect RAGE expression and may be raised in parallel with serum AGE concentrations as a counter-system against AGE-caused tissue damage. Serum concentrations of AGE and sRAGE could therefore become potential therapeutic targets.
Identifiants
pubmed: 30836666
pii: antiox8030055
doi: 10.3390/antiox8030055
pmc: PMC6466542
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Haematol. 1978;60(5):257-68
pubmed: 101012
Clin Chim Acta. 2001 Nov;313(1-2):69-75
pubmed: 11694241
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Cell Tissue Res. 2006 Mar;323(3):475-88
pubmed: 16315007
Curr Med Chem. 2006;13(17):1971-8
pubmed: 16842191
Metabolism. 2006 Sep;55(9):1227-31
pubmed: 16919543
Neoplasma. 2007;54(3):219-24
pubmed: 17447853
J Clin Invest. 2007 May;117(5):1175-83
pubmed: 17476347
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):e32; author reply e33-4
pubmed: 17522392
Diabetes Metab Res Rev. 2008 Feb;24(2):109-14
pubmed: 17694504
Cancer Invest. 2007 Dec;25(8):720-5
pubmed: 18058469
Nat Clin Pract Endocrinol Metab. 2008 May;4(5):285-93
pubmed: 18332897
Biochem Biophys Res Commun. 2008 May 23;370(1):1-5
pubmed: 18355449
Antioxid Redox Signal. 2008 Oct;10(10):1699-712
pubmed: 18576917
FASEB J. 2008 Oct;22(10):3716-27
pubmed: 18603587
J Biol Chem. 2008 Dec 19;283(51):35507-16
pubmed: 18952609
Pharmacol Res. 2009 Sep;60(3):174-8
pubmed: 19646657
Neoplasma. 2010;57(1):55-61
pubmed: 19895173
Carcinogenesis. 2010 Mar;31(3):334-41
pubmed: 20028726
Annu Rev Immunol. 2010;28:367-88
pubmed: 20192808
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
Front Biosci (Schol Ed). 2011 Jan 01;3:768-76
pubmed: 21196410
Bone. 2011 Aug;49(2):174-83
pubmed: 21530698
Cancer Res. 2011 May 15;71(10):3582-9
pubmed: 21540233
World J Diabetes. 2011 Jul 15;2(7):108-13
pubmed: 21860695
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):650-60
pubmed: 21906430
Biomarkers. 2011 Dec;16(8):718-9
pubmed: 22103587
Cancer Invest. 2012 Jan;30(1):20-6
pubmed: 22236186
Inflamm Res. 2012 Oct;61(10):1063-7
pubmed: 22674324
Horm Metab Res. 2013 May;45(5):387-90
pubmed: 23225247
Curr Opin Lipidol. 2013 Feb;24(1):4-11
pubmed: 23298958
Expert Rev Hematol. 2013 Jun;6(3):317-25
pubmed: 23782085
Aging Dis. 2014 Jun 01;5(3):212-7
pubmed: 24900944
Glycobiology. 2014 Nov;24(11):979-90
pubmed: 24946787
Allergy. 2015 Apr;70(4):436-42
pubmed: 25630934
Asian Pac J Cancer Prev. 2015;16(7):2725-9
pubmed: 25854354
Exp Ther Med. 2015 May;9(5):1895-1900
pubmed: 26136911
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):1-10
pubmed: 26847418
Life Sci. 2016 Apr 15;151:139-146
pubmed: 26874030
Cancer Epidemiol. 2016 Jun;42:115-23
pubmed: 27100837
Biochem Biophys Res Commun. 2016 Sep 2;477(4):963-969
pubmed: 27387233
Oxid Med Cell Longev. 2016;2016:4197815
pubmed: 27781076
J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1203-1208
pubmed: 28078875
Cancer Lett. 2017 Apr 1;390:153-159
pubmed: 28111136
FEBS Open Bio. 2016 Dec 22;7(2):122-132
pubmed: 28174680
Front Oncol. 2017 Mar 20;7:43
pubmed: 28373964
Mar Drugs. 2017 Apr 21;15(4):null
pubmed: 28430159
J Med Chem. 2017 Sep 14;60(17):7213-7232
pubmed: 28482155
Metabolism. 2017 Jun;71:64-69
pubmed: 28521879
Leuk Lymphoma. 2017 Dec;58(12):2934-2938
pubmed: 28679295
Science. 2017 Dec 1;358(6367):
pubmed: 29191879
Blood Adv. 2017 Sep 29;1(22):1911-1918
pubmed: 29296837
Biochem J. 1997 Mar 1;322 ( Pt 2):567-73
pubmed: 9065778